AChR phosphorylation and indirect inhibition of AChR function in seronegative MG

Neurology

Volumn 59, Issue 11, 2002, Pages 1682-1688

  Plested, C P ^a   Tang, T ^a   Spreadbury, I ^a   Littleton, E T ^a   Kishore, U ^a   Vincent, Angela ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MEMBRANE RECEPTOR; PHOSPHOTRANSFERASE;

ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; ELECTROPHYSIOLOGY; ENZYME ASSAY; HUMAN; HUMAN CELL; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; PATHOPHYSIOLOGY; PLASMA FACTOR; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SERODIAGNOSIS;

EID: 0037058787     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000041625.41937.FF     Document Type: Article

References (29)

1. Drachman DB. Myasthenia gravis. N Engl J Med 1994;330: 1797-1810.
2. Soliven BC, Lange DJ, Penn AS, et al. Seronegative myasthenia gravis. Neurology 1988;38:514-517.
3. Sanders DB, Andrews PI, Howard JF, Massey JM. Seronegative myasthenia gravis. Neurology 1997;48:S40-S45.
4. Vincent A, Li Z, Hart A, et al. Seronegative myasthenia gravis: Evidence for plasma factor(s) interfering with acetylcholine receptor function. Ann N Y Acad Sci 1993;681:529-538.
5. Mossman S, Vincent A, Newsom-Davis J. Myasthenia gravis without acetylcholine receptor antibody: A distinct disease entity. Lancet 1986;1:116-119.
6. Mier AK, Havard CW. Diaphragmatic myasthenia in mother and child. Postgrad Med J 1985;61:725-727.
7. Burges J, Vincent A, Molenaar PC, Newsom-Davis J, Peers C, Wray D. Passive transfer of seronegative myasthenia gravis to mice. Muscle Nerve 1994;17:1393-1400.
8. Evoli A, Batocchi AP, Lo Monaco M, et al. Clinical heterogeneity of seronegative myasthenia gravis. Neuromuscul Disord 1996;6:155-161.
9. Blaes F, Beeson D, Plested P, Lang B, Vincent A. IgG from. "seronegative" myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor. Ann Neurol 2000;47:504-510.
10. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Autoantibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-368.
11. Yamamoto T, Vincent A, Ciulla TA, Lang B, Johnston I, Newsom-Davis J. Seronegative myasthenia gravis: A plasma factor inhibiting agonist-induced acetylcholine receptor function copurifies with IgM. Ann Neurol 1991;30:550-557.
12. Barrett-Jolley R, Byrne N, Vincent A, Newsom-Davis J. Plasma from patients with seronegative myasthenia gravis inhibit nAChR responses in the TE671/RD cell line. Pflügers Arch 1994;428:492-498.
13. Plested CP, Newsom-Davis J, Vincent A. Seronegative myasthenia plasmas and non-IgG fractions transiently inhibit nAChR function. Ann N Y Acad Sci 1998;841:501-504.
14. Li Z, Forester N, Vincent A. Modulation of acetylcholine receptor function in TE671 cells by non-AChR ligands: Possible relevance to seronegative myasthenia gravis. J Neuroimmunol 1996;64:179-183.
15. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: Results in 153 validated cases and 1967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985;48:1246-1252.
16. Beeson D, Amar M, Bermudez I, Vincent A, Newsom-Davis J. Stable expression of the adult subtype of human muscle acetylcholine receptor in the TE671 cell line. Neurosci Lett 1996; 207:57-60.
17. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ. Improved patch clamp techniques for high-resolution current recordings from cells and cell-free membrane patches. Pflügers Arch 1981;391:85-100.
18. Zachayus J-L, Plas C. Insulin receptor beta-subunit serine phosphorylation in permeabilized cultured fetal rat hepatocytes. Mol Cell Endocrinol 1993;92:15-23.
19. Colca JR, Wolf BA, Comens PG, McDaniel ML. Protein phosphorylation in permeabilized pancreatic islet cells. Biochem J 1985;228:529-536.
20. Jacobson L, Beeson D, Tzartos S, Vincent A. Monoclonal antibodies raised against human acetylcholine receptor bind to all five subunits of the fetal isoform. J Neuroimmunol 1999;98: 112-120.
21. Heasley LE, Johnson GL. Detection of nerve growth factor and epidermal growth factor-regulated protein kinases in PC12 cells with synthetic peptide substrates. Mol Pharmacol 1989;35:331-338.
22. Kemp BE. Phosphorylation of acyl and dansyl derivatives of the peptide Leu-Arg- Arg-Ala-Ser-Leu-Gly by the cAMP-dependent protein kinase. J Biol Chem 1980;255:2914-2918.
23. Cheng HC, Kemp BE, Pearson RB, et al. A potent synthetic peptide inhibitor of the cAMP-dependent protein kinase. J Biol Chem 1986;261:989-992.
24. Swope SL, Qu Z, Huganir RL. Phosphorylation of the nicotinic acetylcholine receptor by protein tyrosine kinases. Ann N Y Acad Sci 1995;757:197-214.
25. + flux into TE671 cell line. J Neuroimmunol 1988;19:141-148.
26. Kusner LL, Kaminski HJ. Nitric oxide synthase is concentrated at the skeletal muscle endplate. Brain Res 1996;730: 238-242.
27. Chao DS, Silvagno F, Xia H, Cornwell TL, Lincoln TM, Bredt DS. Nitric oxide synthase and cyclic GMP-dependent protein kinase concentrated at the neuromuscular endplate. Neuroscience 1997;76:665-672.
28. Bufler J, Pitz R, Czep M, Wick M, Franke C. Purified IgG from seropositive and seronegative patients with myasthenia gravis reversibly blocks currents through nicotinic acetylcholine receptors. Ann Neurol 1998;43:458-464.
29. Poea S, Guyon T, Bidault J, Bruand C, Mouly V, Berrih-Aknin S. Modulation of acetylcholine receptor expression in seronegative myasthenia gravis. Ann Neurol 2000;48:696-705.